Clinical trial
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That…
NCT00089206 · University of Virginia, Other · Completed
Key facts
| NCT number | NCT00089206 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery |
| Official title | Vaccination With Synthetic Melanoma Peptides Administered With GM-CSF-in-Adjuvant in Patients With Advanced Melanoma |
| Lead sponsor | University of Virginia, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim |
| Enrollment | 7 |
| Start date | Aug 1, 2002 |
| Primary completion | Nov 1, 2005 |
| First posted | Aug 5, 2004 |
| Last update posted | Dec 19, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: